CAR-T cells take on lupus and more in early safety trial
NCT ID NCT06549296
First seen Feb 03, 2026 · Last updated May 01, 2026 · Updated 9 times
Summary
This early-phase study tests a new treatment called RD06-04, which uses a patient's own immune cells modified to target and destroy harmful B cells. It aims to see if this approach is safe and tolerable for people with active autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. The trial is currently on hold and plans to enroll 12 adults aged 18 to 70.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Xuzhou Medical University Affiliated Hospital
Xuzhou, Jiangsu, 221000, China
Conditions
Explore the condition pages connected to this study.